By Billy Gray
Roche Holding is scheduled to report results for the third quarter on Thursday. Here is what you need to know:
SALES FORECAST: The Swiss pharmaceutical group is expected to post sales of 15.17 billion Swiss francs ($19.05 billion) according to consensus estimates provided by Visible Alpha, compared with 15.14 billion francs in the same period last year. Currency movements are expected to be a material headwind in the third quarter, UBS analyst Matthew Weston said in a research note.
Shares in Roche fell 1% during the third quarter, but rose 8.4% since the beginning of the year through Tuesday's close.
WHAT TO WATCH:
--DRUG PRICING: The impact of President Trump's plan to lower U.S. prescription drug prices in line with other developed nations is at the top of investors' minds in pharma companies. Pfizer and AstraZeneca recently reached deals with the White House and analysts at Berenberg said other big pharma companies were likely to make similar moves. Trump has outlined tariffs on drugs from pharmaceutical companies that aren't building plants in the U.S., but Roche in April pledged to spend $50 billion in the country over the next five years.
--PHARMA PIPELINE: Roche's recent update on its pharma business showed it faces no imminent patent cliff, analysts at Bank of America said. UBS's Weston said Roche's comments on its pipeline, and particularly the outcome of a recent late-stage trial of its giredestrant drug candidate for breast cancer, will be in focus. Roche said on Saturday that giredestrant outperformed the standard-of-care in a study with patients that carried a specific genetic alteration. While the results showed the drug improved results for patients with a certain type of breast cancer, it will be up to regulators to decide whether to give green light for the full patient population, Vontobel analyst Stefan Schneider said.
Write to Billy Gray at william.gray@wsj.com
(END) Dow Jones Newswires
October 22, 2025 07:42 ET (11:42 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Comments